Table 7 Overall and progression-free survival of patients treated by nivolumab using cox proportional hazard regression model
Variable | Overall survival | Progression-free survival | ||||
|---|---|---|---|---|---|---|
HR | 95% C.I. | p value | HR | 95% C.I. | p value | |
Sex | ||||||
 male | 1 |  |  | 1 |  |  |
 female | 1.196 | 0.608–2.353 | 0.604 | 1.714 | 0.913–3.220 | 0.094 |
Age | ||||||
  ≤ 66 | 1 |  |  | 1 |  |  |
  > 66 | 1.005 | 0.565–1.786 | 0.987 | 0.8503 | 0.492–1.470 | 0.561 |
ECOG PS | ||||||
 0 | 1 |  |  | 1 |  |  |
  ≥ 1 | 3.472 | 1.236–9.753 | 0.018 | 1.49 | 0.698–3.182 | 0.303 |
Primary site | ||||||
 Gastric | 1 |  |  | 1 |  |  |
 Esophagogastric junction | 0.8768 | 0.392–1.963 | 0.749 | 0.669 | 0.301–1.487 | 0.324 |
Disease status | ||||||
 Metastatic | 1 |  |  | 1 |  |  |
 Relapsed | 1.241 | 0.321–4.798 | 0.755 | 0.903 | 0.4899.-1.665 | 0.744 |
Histological type | ||||||
 Intestinal type | 1 |  |  | 1 |  |  |
 Diffuse type | 0.881 | 0.490–1.581 | 0.67 | 1.067 | 0.622–1.833 | 0.813 |
Organ with metastasis | ||||||
 1 | 1 |  |  | 1 |  |  |
  ≥ 2 | 1.656 | 0.858–3.196 | 0.133 | 1.699 | 0.932–3.097 | 0.084 |
Lymph node metastasis | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 0.995 | 0.529–1.871 | 0.987 | 0.959 | 0.539–1.707 | 0.888 |
Hematogenous metastasis | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 1.576 | 0.871–2.853 | 0.133 | 1.491 | 0.860–2.584 | 0.155 |
Peritoneal metastasis | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 1.049 | 0.591–1.862 | 0.8701 | 0.969 | 0.566–1.659 | 0.909 |
Previous treatment regimens | ||||||
 2 | 1 |  |  | 1 |  |  |
  ≥ 3 | 1.325 | 0.742–2.367 | 0.342 | 1.103 | 0.636–1.911 | 0.728 |
HER-2 status | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 1.923 | 0.985–3.754 | 0.055 | 1.7 | 0.886–3.262 | 0.111 |
Prior trastuzumab | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 2.123 | 1.036–4.352 | 0.040 | 1.672 | 0.844–3.313 | 0.141 |
Prior ramucirumab | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 1.082 | 0.504–2.319 | 0.841 | 1.265 | 0.616–2.596 | 0.522 |
Treatment period before nivolumab | ||||||
  ≤ 14.9 | 1 |  |  | 1 |  |  |
  > 14.9 | 0.924 | 0.521–1.639 | 0.787 | 0.889 | 0.520–1.519 | 0.666 |
Immune-related adverse events (≥grade 2) | ||||||
 no | 1 |  |  | 1 |  |  |
 yes | 0.3174 | 0.124–0.815 | 0.017 | 0.615 | 0.298–1.271 | 0.19 |
Best overall response | ||||||
 Non-responder | 1 |  |  | 1 |  |  |
 Responder | 0.14 | 0.065–0.302 | < 0.001 | 0.036 | 0.011–0.113 | < 0.001 |
Subsequent chemotherapy after nivolumab | ||||||
 No | 1 |  |  | 1 |  |  |
 Yes | 0.31 | 0.169–0.567 | < 0.001 | 0.596 | 0.346–1.025 | 0.061 |